| |
The press had reports on January 21, 2003 that Thermax Limited is eying acquisitions for inorganic growth with an increased focus on the company's international operations.
The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.
Thermax Limited has vide its letter inter-alia stated, "In the ordinary course of business, as a part of its ongoing activity, the Company considers development of new markets and augmenting manufacturing facilities. However, no definitive plans in this regard have been drawn up as on date for making investment towards development of new market or augmenting manufacturing facilities other than what is required during the normal course of business operations. As on date the Company also does not have any specific acquisition plans.”
Top
The press had reports on January 21, 2003 that Kopran Limited has entered into contract-manufacture a range of formulations for global pharma major Pliva. Further the company has also inked a memorandum of understanding (MOU) with German company Helm AG to market its bulk roxythromycin in Europe.
The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.
Kopran Limited has vide its letter inter-alia stated, "We would like to clarify that we are in the international business and accordingly entered into an agreement to contract-manufacture a range of formulations for global pharma major Pliva. We would further like to clarify that the company is in the development of marketing Bulk Roxythromycin in Europe through Germany business partner Helm. We are in the international business and these are normal transactions/MOU/agreements which are entered/ to be entered from time to time."
Top
The Exchange has successfully completed its 728th Normal Settlement (Rolling T+3 following SEBI directive) since inception i.e., Settlement Number N - 2003013 on January 22, 2003. The settlement statistics are as follows:
| Particulars |
Values |
| |
N - 2003013 |
| Total traded quantity (lakhs) |
1474.14 |
| Total traded value (Rs. In Crores) |
2624.96 |
| Total value of the settlement (Securities) (Rs. In Crores) |
416.23 |
| Total value of the settlement (Funds) (Rs. In Crores) |
157.56 |
| Shortages for the settlement |
0.44% |
| % of Delivery ( No. of shares delivered / No. of shares traded ) |
27.49% |
Top
|
|